News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Biogen Idec, Inc. (Massachusetts) Earnings up on Higher MS Drug Sales
July 20, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Biogen Idec Inc (BIIB.O) said on Tuesday its second-quarter earnings rose on higher sales of its multiple sclerosis drugs. Net profit rose to $293.4 million, or $1.12 a share, from $143 million, or 49 cents a share, a year earlier.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Biogen
MORE ON THIS TOPIC
Immunology and inflammation
Novartis Unites With Relation in $1.7B Inflammatory Skin Disease Pact
December 9, 2025
·
2 min read
·
Tristan Manalac
Cancer
GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya
December 8, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To $1.25B
December 4, 2025
·
2 min read
·
Tristan Manalac
Opinion
Even Early Stage Biotechs Can’t Ignore Tariffs
December 3, 2025
·
4 min read
·
Josh Medow